Inovio (INO) announced that peer-reviewed data from its Phase 1/2 clinical trial with INO-3107 as a potential treatment for recurrent ...

PITTSBURGH (AP) — PITTSBURGH (AP) — The Kraft Heinz Company (KHC) on Wednesday reported fourth-quarter earnings of $2.13 billion. On a per-share basis, the Pittsburgh-based company said it had net ...

Precigen has a market cap of $468mn and a cash runway into 2026, but needs more funds for commercialization. Check out my ...

Poster will describe loss of detectable HPV-6 in Recurrent Respiratory Papillomatosis patients following treatment with INO-3107 American Association for Cancer Research – Immuno-Oncology Discovery ...

Recurrent respiratory papillomatosis (RRP) is a disease of the upper airway presenting with exophytic wart-like lesions. These lesions are considered benign with less than a 1–5% chance of malignant ...

PRGN-2012 is under clinical development by Precigen and currently in Phase III for Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma). According to GlobalData, ...

The Opportunity Equity Strategy outperformed the S&P 500 in 2024, driven by strategic investments in undervalued cyclicals, healthcare, and energy sectors. Precigen's private deal and potential ...

a gene therapy being investigated as a treatment option for adult patients with recurrent respiratory papillomatosis (RRP). RRP is a rare condition when benign tumors called papillomas grow in the ...